Advanced Filters
noise

Coral Gables, Florida Clinical Trials

A listing of Coral Gables, Florida clinical trials actively recruiting patient volunteers.

Found 616 clinical trials
A Amy Megerle

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

18 - 75 years of age All Phase 1/2
D Deena Cilien, DPT

Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI)

The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).

21 - 70 years of age All Phase N/A
R Reshma L Mahtani, D.O.

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast …

18 years of age All Phase 2
B Benjamin J Rich, MD

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

The purpose of this prostate cancer research study is to learn about: Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; Preserving quality of life after radiation therapy; Leveraging imaging results from prostate-specific membrane antigen (PSMA) …

18 years of age Male Phase 2

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

18 years of age All Phase 1/2
U US GSK Clinical Trials Call Center

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to less than 12 years of age, …

6 - 12 years of age All Phase 1/2

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

18 years of age All Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

18 years of age All Phase 1/2
J Jason Luke

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

18 years of age All Phase 1
M Maylen Perez

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies

A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately …

1 - 4 years of age All Phase 4

Simplify language using AI